Adherium Ltd
ASX:ADR
Intrinsic Value
Adherium Ltd. is an international respiratory eHealth company, which is focused on patient medication adherence, remote monitoring, and data management solutions for patients, payers, and providers. [ Read More ]
The intrinsic value of one
ADR
stock under the Base Case scenario is
15.787
AUD.
Compared to the current market price of 0.029 AUD,
Adherium Ltd
is
Undervalued by 100%.
Adherium Ltd's market capitalization is 9.7m AUD.
ADR stock price is 0.029 AUD.
ADR stock price (0.029 AUD) is 100% less than its Intrinsic Value (15.787 AUD).
ADR stock price (0.029 AUD) is 91% less than its Relative Value (0.333 AUD). Open Relative Valuation
ADR.
ADR's Revenue has grown by an exceptional 25% over the past 12 months.
ADR has positive Gross Profit for the last twelve months.
ADR's ROE (Return on Equity) has significantly decreased in the last 3 years from 570% to -99%.
ADR's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 2 004% to -611%.
ADR has negative Operating Income for the last twelve months.
ADR has negative Net Income for the last twelve months.
ADR's ROE (Return on Equity) for the past 12 months is negative and is equal to -99%.
ADR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -611%.
ADR's Revenue is forecast to grow at a rate of 94% per year over the next 3 years.
ADR's short-term assets (7m AUD) exceed its short-term liabilties (3m AUD).
ADR's long-term assets (7m AUD) exceed its long-term liabilties (3m AUD).
ADR's Revenue has been growing by an exceptional 56% per year for the last 3 years.
ADR has negative Free Cash Flow for the last twelve months.
ADR has negative three-year average ROE (Return on Equity): -44%. The company is not efficient at transforming stockholders' equity into net income.
ADR has very high three-year average ROIC (Return on Invested Capital): 225%. The company is very efficient at using invested capital to generate operating income.
ADR's D/E (Debt to Equity) is very low and is equal to 0.
ADR's Altman Z-Score is very low and is equal to -22.1.
ADR earns more than enough operating income (-9m AUD) to safely cover interest payments on its debt (-2k AUD).
Fundamental Analysis
Adherium Ltd
Balance Sheet Decomposition
Adherium Ltd
| Current Assets | 7.1m |
| Cash & Short-Term Investments | 3.1m |
| Receivables | 2.3m |
| Other Current Assets | 1.7m |
| Non-Current Assets | 116k |
| PP&E | 96.5k |
| Intangibles | 19.5k |
| Current Liabilities | 2.6m |
| Accounts Payable | 2m |
| Other Current Liabilities | 618.4k |
Earnings Waterfall
Adherium Ltd
|
Revenue
|
4.1m
AUD
|
|
Cost of Revenue
|
-1.3m
AUD
|
|
Gross Profit
|
2.8m
AUD
|
|
Operating Expenses
|
-11.8m
AUD
|
|
Operating Income
|
-9.1m
AUD
|
|
Other Expenses
|
361.4k
AUD
|
|
Net Income
|
-8.7m
AUD
|
Free Cash Flow Analysis
Adherium Ltd
What is Free Cash Flow?
ADR Profitability Score
Profitability Due Diligence
Adherium Ltd's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Adherium Ltd's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
ADR Solvency Score
Solvency Due Diligence
Adherium Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Adherium Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADR Price Targets Summary
Adherium Ltd
Shareholder Return
ADR Price
Adherium Ltd
| Average Annual Return | -36.92% |
| Standard Deviation of Annual Returns | 31.77% |
| Max Drawdown | -97% |
| Market Capitalization | 9.7m AUD |
| Shares Outstanding | 333 440 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Adherium Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Adherium Ltd. is an international respiratory eHealth company, which is focused on patient medication adherence, remote monitoring, and data management solutions for patients, payers, and providers. The company offers a range of smart devices for respiratory medications globally. Its Smartinhaler platform supports asthma and chronic obstructive pulmonary disease (COPD) medication adherence solution. The Bluetooth enabled Smartinhaler medication sensors wrap around patients existing inhalers and automatically send usage data to their smartphone. The Smartinhaler application enables patients and healthcare professionals to track medication adherence, set daily reminders, and discover insights into their medication usage. Its application also enables real-time reporting, monitoring, storing and analysis of inhaler use. The SmartinhalerLive platform uses wireless communications technology to provide real time data collection and reporting from the its Smartinhalers.
You don't have any saved screeners yet
